Data Insights

Sacituzumab govitecan by Gilead Sciences for Small-Cell Lung Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Small-Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Small-Cell Lung Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Gastric Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Gastric Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Cervical Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Cervical Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Cervical Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Epithelial Ovarian Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Epithelial Ovarian Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Thymic Carcinoma: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Thymic Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Thymic Carcinoma

Data Insights

Sacituzumab govitecan by Gilead Sciences for Endometrial Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase III for Endometrial Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Endometrial Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Bladder Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Bladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Bladder Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Sacituzumab govitecan by Gilead Sciences for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC)....

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Muscle Invasive Bladder Cancer (MIBC)

Data Insights

Sacituzumab govitecan by Gilead Sciences for Colorectal Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Colorectal Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Peritoneal Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Peritoneal Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Fallopian Tube Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sacituzumab Govitecan in Fallopian Tube Cancer

Data Insights

Sacituzumab govitecan by Gilead Sciences for Glioblastoma Multiforme (GBM): Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Glioblastoma Multiforme (GBM). According to...

Data Insights

Sacituzumab govitecan by Gilead Sciences for Ovarian Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Ovarian Cancer. According to GlobalData,...

Data Insights

Sacituzumab govitecan by Gilead Sciences for Anaplastic Thyroid Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Anaplastic Thyroid Cancer. According to...

Data Insights

Sacituzumab govitecan by Gilead Sciences for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Kidney Cancer (Renal Cell Cancer)....

Data Insights

Sacituzumab govitecan by Gilead Sciences for Esophageal Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Esophageal Cancer. According to GlobalData,...

Data Insights

Sacituzumab govitecan by Gilead Sciences for Hepatocellular Carcinoma: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...

Data Insights

Sacituzumab govitecan by Gilead Sciences for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Squamous Non-Small Cell Lung Cancer....

Data Insights

Sacituzumab govitecan by Gilead Sciences for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...